Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Olga Kulemina, MD, Nadia Siordia, MD, Konstantin Bogdanov, PhD, Julia Alexeeva, MD PhD, Larisa Girshova, MD PhD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD PhD

Blood (2019) 134 (Supplement_1): 5138.

https://doi.org/10.1182/blood-2019-129815

Published: 2019

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia

Sergei M. Kulikov, PhD, Anna G Turkina, Prof., MD, Anton Kulikovsky, Olga Lazareva, PhD, Sergey Kutsev, Prof., MD, PhD, Elza Lomaia, MD, Andrey Zaritskey, MD PhD, Anatoly Golenkov, MDProf, Tatiana Pospelova, MD PhD, Satokhin Yuri, MD PhD, Tatiana Konstantinova, MD PhD, Elena N. Parovichnikova, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2018) 132 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2018-99-114700

Published: 2018

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

Journal Articles

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Natalia Lazorko, MD, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Irina Martynkevich, Mikhail Fominykh, MD, Anna Silyutina, MD, Katerina Ovsiannikova, Nadia Siordia, MD, Andrey Zaritskey, Elena Machulaytene, MD

Blood (2017) 130 (Supplement 1): 5255.

https://doi.org/10.1182/blood.V130.Suppl_1.5255.5255

Published: 2017

Journal Articles

Is Quality of Life (QOL) Predictive for Clinical Response in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients Treated with Dasatinib?

Tatiana Ionova, DSc, Natalia Bulieva, MD, Anatoly Golenkov, MDProf, Taras Gritsenko, MD, Lilia Kozlova, MD Prof, Galina Kuchma, MD PhD, Elza Lomaia, MD, Elena Machulaytene, MD, Tatiana Nikitina, PhD, Natalia Novitskaya, MD PhD, Elena Usacheva, MD PhD, Tatiana Shneider, MD, Elena Trifonova, MD PhD, Olga Vinogradova, MD PhD, Anna Zinkovskaya

Blood (2017) 130 (Supplement 1): 2181.

https://doi.org/10.1182/blood.V130.Suppl_1.2181.2181

Published: 2017

Journal Articles

Survival Outcome of Imatinib Mono Therapy in Chronic Phase Chronic Myeloid Leukemia - a Single Center Experience in Belorus

Janna Kozich, MD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD

Blood (2016) 128 (22): 5452.

https://doi.org/10.1182/blood.V128.22.5452.5452

Published: 2016

Journal Articles

Incidence of Elevated Expression of wt1 in Primary Myelofibrosis (pmf) and Postpv-, Postet Myelofibrosis and Its Dynamics during Ruxolitinib Treatmeny

Nadiya Siordiya, Ekaterina Lisina, MD, Pavel Butylin, PhD, Natalia Matuhina, Konstantin Bogdanov, Anna Silutina, Elza Lomaia, MD PhD, Andrey Zaritskiy, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 5498.

https://doi.org/10.1182/blood.V128.22.5498.5498

Published: 2016

Journal Articles

Calreticulin Mutations Variants of ET and PMF Patients Studied in Almazov Medical Research Center Russian Federation

Pavel Butylin, PhD, Natalia Matyuhina, MS, Ekaterina Lisina, MD, Nadia Siordia, MD, Olga Senderova, MD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD

Blood (2016) 128 (22): 5499.

https://doi.org/10.1182/blood.V128.22.5499.5499

Published: 2016

Journal Articles

Quality of Life (QoL) and Clinical Outcomes of Dasatinib Treatment in TKI-Naive and Early Switched from Imatinib Patients with Chronic Myeloid Leukemia in Chronic Phase (CP CML) in a Real World Setting

Tatyana Ionova, PhD, Natalia Bulieva, MD, Olga Vinogradova, MD PhD, Kira Kurbatova, Elza Lomaia, MD PhD, Tatyana Nikitina, MD PhD, Natalia Novitskaya, Anna Rodionova, MD PhD, Elena Usacheva, Marina Chukavina, Marina Shumkova

Blood (2016) 128 (22): 5456.

https://doi.org/10.1182/blood.V128.22.5456.5456

Published: 2016

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Elza Lomaia, MD PhD, Andrey Zaritskey, MD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Mikhail Fominykh, MD, Ekaterina Ovsyannikova, MD, Natalia Lazorko, MD, Natalia Matyuhina, MS, Pavel Butylin, PhD, Elena Machyulaitene, MD, Evgenia Salamatova, MD, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 4051.

https://doi.org/10.1182/blood.V126.23.4051.4051

Published: 2015

Journal Articles

Patient-Reported Outcomes in Myelofibrosis Patients Help to Identify Patients' Needs

Tatyana Ionova, PhD, Tatyana Nikitina, MD PhD, Elza Lomaia, MD PhD, Alexandr Myasnikov, MD PhD, Tatyana Pospelova, MD PhD, Andrey Evseev, MD PhD, Taras Gritsenko, MD PhD, Anna Lyamkina, MD PhD, Elena Machulaytene, MD PhD, Elena Usacheva, MD PhD, Anna Rodionova, MD PhD, Kira Kurbatova

Blood (2015) 126 (23): 5198.

https://doi.org/10.1182/blood.V126.23.5198.5198

Published: 2015

Journal Articles

Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities

Tatyana Ionova, PhD, Tatyana Nikitina, MD PhD, Galina Kuchma, MD PhD, Elza Lomaia, MD PhD, Tatyana Shnaider, MD PhD, Elena Usacheva, MD PhD, Kira Kurbatova

Blood (2015) 126 (23): 5147.

https://doi.org/10.1182/blood.V126.23.5147.5147

Published: 2015

Journal Articles

“FLAG” Regimen Induces Deep, Although Short-Term, Responses in Patients Resistant to Tyrosine Kinases Inhibitors in BP CML.

Ekaterina Romanova, MD, Larisa Girshova, MD, Nadia Siordia, MD, Elena Goriunova, MD, Dmitry Motorin, MD PhD, Elza Lomaia, MD PhD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 5534.

https://doi.org/10.1182/blood.V124.21.5534.5534

Published: 2014

Journal Articles

Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience

Elza Lomaia, MD, PhD, Ekaterina Romanova, MD, Larisa Girshova, MD, Yulia Alexeeva, MD, PhD, Eugenia Sbityakova, MD, Elena Goriunova, MD, Vladimir Strugov, MD, Natalia Lazorko, MD, Nadia Siordia, MD, Diana Mescheryakova, MD, Tatiana Silina, MD, Dmitry Motorin, MD, PhD, Andrey Zaritskey, MD, PhD

Blood (2013) 122 (21): 5173.

https://doi.org/10.1182/blood.V122.21.5173.5173

Published: 2013

NARROW

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Is Quality of Life (QOL) Predictive for Clinical Response in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients Treated with Dasatinib?

Survival Outcome of Imatinib Mono Therapy in Chronic Phase Chronic Myeloid Leukemia - a Single Center Experience in Belorus

Incidence of Elevated Expression of wt1 in Primary Myelofibrosis (pmf) and Postpv-, Postet Myelofibrosis and Its Dynamics during Ruxolitinib Treatmeny

Calreticulin Mutations Variants of ET and PMF Patients Studied in Almazov Medical Research Center Russian Federation

Quality of Life (QoL) and Clinical Outcomes of Dasatinib Treatment in TKI-Naive and Early Switched from Imatinib Patients with Chronic Myeloid Leukemia in Chronic Phase (CP CML) in a Real World Setting

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Patient-Reported Outcomes in Myelofibrosis Patients Help to Identify Patients' Needs

Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities

“FLAG” Regimen Induces Deep, Although Short-Term, Responses in Patients Resistant to Tyrosine Kinases Inhibitors in BP CML.

Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only